Precision Oncology with AI

What is Precision Oncology?

Precision oncology uses genomic profiling and AI to match cancer patients with optimal targeted therapies based on their tumor's molecular characteristics. Unlike traditional oncology, which treats cancer types with standardized chemotherapy protocols, precision oncology identifies the specific genetic drivers of each patient's tumor and selects therapies that target those molecular vulnerabilities. This approach has transformed outcomes for specific cancer subtypes: EGFR-mutant NSCLC patients receiving osimertinib show 71% response rates versus 31% with standard chemotherapy, and ALK-rearranged NSCLC patients achieve 83% response rates with alectinib.

The core challenge is tumor heterogeneity—a single tumor contains millions of genetically distinct subclones, and metastatic sites may harbor different driver mutations than the primary tumor. AI addresses this by integrating multi-omic data (whole-exome sequencing, RNA-seq, proteomics, digital pathology) to identify the dominant molecular pathways driving tumor growth, predict drug response from genomic features, and detect emerging resistance mutations through serial liquid biopsies. Machine learning models trained on large genomic databases (TCGA, AACR GENIE, MSK-IMPACT) achieve AUROC scores of 0.82-0.91 for predicting therapy response from molecular profiles.

AI-powered precision oncology has been deployed at major cancer centers including Memorial Sloan Kettering (MSK-IMPACT platform), MD Anderson (APOLLO database), and the Dana-Farber Cancer Institute, where AI models analyze genomic data from 50,000+ patients to recommend targeted therapies and clinical trial matches. The field is moving toward real-time ctDNA monitoring, where AI detects resistance mutations from blood draws every 4-6 weeks, enabling adaptive therapy switching before radiographic progression.

Tumor Mutational Burden

Tumor Mutational Burden Calculation

Where each parameter means:

• — the tumor mutational burden, measured in mutations per megabase (mut/Mb); the FDA threshold for TMB-high is ≥10 mut/Mb
• — the count of non-synonymous somatic mutations in the tumor sample (excluding germline variants and synonymous mutations)
• — the size of the sequenced coding region in megabases (typically 30-50 Mb for whole-exome sequencing)
• Clinical meaning: TMB-high tumors generate more neoantigens, making them more visible to the immune system and more likely to respond to immune checkpoint inhibitors (ICI)
• Why it matters: TMB-high predicts 40% objective response rate (ORR) to pembrolizumab vs. 15% for TMB-low; FDA approved pembrolizumab for TMB-high solid tumors regardless of cancer type

Immunotherapy Response Prediction

Where each parameter means:

• — the predicted probability that the patient will respond to immune checkpoint inhibitor therapy, ranging from 0 to 1
• — the sigmoid function that maps the linear combination to a probability
• — the number of biomarkers integrated into the prediction model (typically 5-10 features)
• — the learned weight for biomarker , determined by logistic regression or neural network training on clinical response data
• — a feature transformation of biomarker (e.g., log-transform for TMB, binary for MSI status, continuous for PD-L1 TPS)
• — individual biomarker values: TMB, PD-L1 tumor proportion score, microsatellite instability status, immune cell infiltration, gene expression signatures
• Clinical meaning: Models achieving AUROC > 0.80 can stratify patients into likely responders vs. non-responders, avoiding unnecessary toxicity in non-responders
• Why it matters: Only 20-40% of patients respond to ICI therapy; accurate prediction prevents unnecessary immune-related adverse events in non-responders

Drug Sensitivity Score

Where each parameter means:

• — the drug sensitivity score quantifying how sensitive a tumor is to a specific drug relative to a reference cell line
• — the number of drug-cell line pairs used for comparison
• — the weight for comparison , based on genomic similarity between the patient tumor and cell line
• — the half-maximal inhibitory concentration for drug in the reference cell line (lower = more sensitive)
• — the median across all cell lines for normalization
• Clinical meaning: Negative DSS indicates the patient tumor is more sensitive than average; positive DSS indicates resistance
• Why it matters: Enables drug ranking based on predicted sensitivity, guiding therapy selection before treatment initiation

Python Implementation

import torch
import torch.nn as nn
import numpy as np

class GenomicRiskModel(nn.Module):
    """Multi-task model for immunotherapy response and survival prediction."""
    def __init__(self, n_genes=500, hidden_dim=128, n_outputs=3):
        super().__init__()
        self.encoder = nn.Sequential(
            nn.Linear(n_genes, hidden_dim), nn.BatchNorm1d(hidden_dim),
            nn.ReLU(), nn.Dropout(0.4),
            nn.Linear(hidden_dim, hidden_dim), nn.BatchNorm1d(hidden_dim),
            nn.ReLU(), nn.Dropout(0.3))
        self.response_head = nn.Linear(hidden_dim, n_outputs)
        self.survival_head = nn.Linear(hidden_dim, 1)

    def forward(self, gene_expr):
        features = self.encoder(gene_expr)
        response = self.response_head(features)
        hazard = self.survival_head(features)
        return response, hazard

class DrugResponsePredictor(nn.Module):
    """Cross-attention model for genomic-drug interaction prediction."""
    def __init__(self, genomic_dim=200, drug_dim=50, hidden_dim=64):
        super().__init__()
        self.genomic_encoder = nn.Sequential(
            nn.Linear(genomic_dim, hidden_dim), nn.ReLU())
        self.drug_encoder = nn.Sequential(
            nn.Linear(drug_dim, hidden_dim), nn.ReLU())
        self.cross_attention = nn.MultiheadAttention(hidden_dim, 4, batch_first=True)
        self.predictor = nn.Sequential(
            nn.Linear(hidden_dim, 32), nn.ReLU(),
            nn.Linear(32, 1))

    def forward(self, genomic, drug):
        g = self.genomic_encoder(genomic).unsqueeze(1)
        d = self.drug_encoder(drug).unsqueeze(1)
        combined = torch.cat([g, d], dim=1)
        attn_out, _ = self.cross_attention(combined, combined, combined)
        return self.predictor(attn_out.mean(dim=1))

risk_model = GenomicRiskModel(n_genes=500, n_outputs=3)
gene_expr = torch.randn(8, 500)
response, hazard = risk_model(gene_expr)
print(f'Response logits: {response.shape}')  # [8, 3]
print(f'Hazard ratio: {hazard.shape}')  # [8, 1]

drug_model = DrugResponsePredictor(genomic_dim=200, drug_dim=50)
genomic = torch.randn(8, 200)
drug = torch.randn(8, 50)
ic50_pred = drug_model(genomic, drug)
print(f'Predicted IC50: {ic50_pred.shape}')  # [8, 1]

Real-World Case Study

Memorial Sloan Kettering's MSK-IMPACT platform has performed comprehensive genomic profiling on 75,000+ cancer patients since 2014, matching 37% of patients to targeted therapies or clinical trials based on identified actionable mutations. A 2023 study showed that AI-guided therapy selection based on multi-omic data improved progression-free survival by 4.2 months (median) compared to standard molecular tumor boards. The system identified ALK rearrangements in 4% of NSCLC cases previously classified as "driver-negative," enabling alectinib treatment with 83% response rates. The ctDNA monitoring module detected resistance mutations an average of 2.8 months before radiographic progression, enabling proactive therapy switching.

Common Challenges

Summary

Key Takeaways:

• Precision oncology matches patients to targeted therapies based on genomic profiles, improving response rates from 20-30% to 60-83%
• TMB, MSI, and PD-L1 biomarkers guide immunotherapy eligibility decisions with FDA-approved thresholds
• AI models integrate multiple molecular features for comprehensive drug response prediction (AUROC 0.82-0.91)
• Cross-attention architectures learn genomic-drug interactions for personalized dosing recommendations
• Serial ctDNA monitoring detects resistance mutations 2-3 months before radiographic progression
• Multi-institutional genomic databases (TCGA, GENIE) enable training on 100,000+ patient profiles